for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

McKesson Corporation

MCK

Latest Trade

146.82USD

Change

1.12(+0.77%)

Volume

2,931,215

Today's Range

146.23

 - 

148.64

52 Week Range

106.11

 - 

150.82

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
145.70
Open
147.07
Volume
2,931,215
3M AVG Volume
31.61
Today's High
148.64
Today's Low
146.23
52 Week High
150.82
52 Week Low
106.11
Shares Out (MIL)
185.00
Market Cap (MIL)
26,940.53
Forward P/E
10.14
Dividend (Yield %)
1.13

Next Event

Q2 2020 McKesson Corp Earnings Release

Latest Developments

More

Mckesson Reports First-Quarter Adjusted Earnings Per Share Of $3.31

Change Healthcare Shares Open About 7.7 Pct Above IPO Price In Debut

Mckesson Says CEO John Hammergren's 2019 Compensation Was $17.4 Million - SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About McKesson Corporation

McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare. It operates through two segments: McKesson Distribution Solutions and McKesson Technology Solutions. The distribution solutions segment distributes branded and generic pharmaceutical drugs and other healthcare-related products internationally and provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. Technology Solutions segment provides software and analytics, network solutions and technology-enabled services.

Industry

Biotechnology & Drugs

Contact Info

1 Post St

+1.415.9838300

http://www.mckesson.com

Executive Leadership

Edward A. Mueller

Independent Chairman of the Board

Brian Scott Tyler

President, Chief Executive Officer, Chief Operating Officer, Director

Britt J. Vitalone

Chief Financial Officer, Executive Vice President

Lori Ann Schechter

Executive Vice President, Chief Compliance Officer, General Counsel

Jorge L. Figueredo

Executive Vice President - Human Resources

Key Stats

2.58 mean rating - 19 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

198.5K

2018

208.4K

2019

214.3K

2020(E)

223.0K
EPS (USD)

2017

12.910

2018

12.620

2019

13.570

2020(E)

14.367
Price To Earnings (TTM)
55.06
Price To Sales (TTM)
0.12
Price To Book (MRQ)
3.42
Price To Cash Flow (TTM)
15.89
Total Debt To Equity (MRQ)
97.69
LT Debt To Equity (MRQ)
93.75
Return on Investment (TTM)
3.46
Return on Equity (TTM)
1.22

Latest News

U.S. Drug distributors propose $10 billion to end state lawsuits over opioids: Bloomberg

Drug wholesalers AmerisourceBergen Corp <ABC.N>, McKesson Corp <MCK.N> and Cardinal Health Inc <CAH.N> have proposed a $10 billion settlement for claims that they played a part in the U.S. opioid epidemic, Bloomberg reported on Tuesday, citing people familiar with negotiations...

McKesson escapes generic drug price-fixing lawsuit

McKesson Corp has escaped a proposed class action lawsuit alleging the drug distributor conspired with the manufacturers of thousands of generic medications to fix prices in order to earn billions of dollars.

McKesson meets full-year profit estimates, renews partnership with CVS

U.S. drug distributor McKesson Corp forecast a full-year profit on Wednesday that matched analysts' estimates, easing some fears over drug pricing pressures and costs of opioid-related litigations.

Drug distributor McKesson posts smaller 4th-qtr loss

U.S. drug distributor McKesson Corp reported a smaller fourth-quarter loss on Wednesday, as its surgical distribution business was boosted by the company's recent acquisition of Medical Specialties Distributors LLC.

UPDATE 2-McKesson to pay $37 million to resolve West Virginia opioid lawsuit

Drug distributor McKesson Corp has agreed to pay $37 million to resolve a lawsuit by the state of West Virginia alleging it helped fuel a U.S. opioid epidemic by failing to stop suspicious orders of painkillers by pharmacies in the state.

McKesson to pay $37 million to resolve West Virginia opioid lawsuit

Drug distributor McKesson Corp has agreed to pay $37 million to resolve a lawsuit by the state of West Virginia seeking to hold it responsible for contributing to the opioid epidemic, the state's attorney general said on Thursday.

FDA warns McKesson for shipping 'illegitimate' opioids

The Food and Drug Administration on Tuesday said it had sent a warning letter to drug distributor McKesson Corp after it sent bottles of prescription opioids and other medications to pharmacies that had been tampered with.

McKesson cannot claw back funds owed to subsidiary in Orexigen bankruptcy - judge

Bankrupt obesity-drug maker Orexigen Therapeutics can keep $6.9 million it received from drug distributor McKesson Corp even though the former owes far more than that to a McKesson subsidiary, the judge overseeing the case ruled on Tuesday.

McKesson's Change Healthcare hires IPO underwriters: sources

Change Healthcare LLC, a healthcare technology company majority-owned by U.S. drug wholesaler McKesson Corp <MCK.N>, has hired underwriters for an initial public offering that could value it at as much as $12 billion, including debt, people familiar with the matter said...

BRIEF-McKesson Board Of Directors Elects Brad Lerman As New Independent Director

* MCKESSON BOARD OF DIRECTORS ELECTS BRAD LERMAN AS NEW INDEPENDENT DIRECTOR

BRIEF-McKesson Launches Multi-Year Strategic Growth Initiative; Reaffirms Fiscal 2018 Outlook

* MCKESSON LAUNCHES MULTI-YEAR STRATEGIC GROWTH INITIATIVE; REAFFIRMS FISCAL 2018 OUTLOOK AND PROVIDES PRELIMINARY FISCAL 2019 OUTLOOK

BRIEF-Polarityte Announces Appointment Of Mckesson’S Willie Bogan To Board Of Directors

* POLARITYTE ANNOUNCES APPOINTMENT OF MCKESSON’S WILLIE BOGAN TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Two-Part Note Offering

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL TWO-PART NOTE OFFERING OF UP TO EUR 750 MILLION - SEC FILING Source text : (http://bit.ly/2H0ogwC) Further company coverage:

BRIEF-McKesson Corp Files Preliminary Prospectus Supplement Related To A Potential Notes Due 2028

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL NOTES DUE 2028 OFFERING OF UP TO $600 MILLION - SEC FILING Source text : (http://bit.ly/2G22iIb) Further company coverage:

BRIEF-Mckesson Files Preliminary Prospectus Supplement Related To Potential Offering Of Notes

* MCKESSON CORP FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL OFFERING OF NOTES DUE 2020 - SEC FILING Source text - http://bit.ly/2FUEDJW Further company coverage:

McKesson says drug prices competitive but not volatile like 2017

U.S. drug wholesaler McKesson Corp <MCK.N> said prices of generic drugs were still competitive, but not as volatile as in 2017 when prices fell sharply, which should help the company as it benefits from a major tie-up with Walmart.

CORRECTED-UPDATE 1-Drug distributor McKesson's quarterly profit beats estimates

McKesson Corp posted a better-than-expected quarterly profit, as the biggest U.S. drug distributor continues to benefit from its tie-up with Walmart .

BRIEF-McKesson Reports Q3 Adjusted Earnings Per Share $3.41

* Q3 GAAP EARNINGS PER SHARE $4.32 FROM CONTINUING OPERATIONS

Drug distributor McKesson posts 42.6 pct rise in quarterly profit

McKesson Corp, the biggest U.S. drug distributor, reported a 42.6 percent rise in quarterly profit on Thursday, partly helped by a $370 million tax benefit related to changes to U.S. tax laws.

Kentucky accuses McKesson of helping fuel opioid epidemic

Kentucky's attorney general on Monday accused drug distributor McKesson Corp of helping fuel the opioid epidemic by failing to halt shipments of suspiciously large or frequent orders by pharmacies of prescription painkillers.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up